Moderna, Inc. (MRNA)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ: MRNA). The investigation concerns whether Moderna and certain of its officers and/or directors have violated federal securities laws.


On January 18, 2021, Moderna issued a statement acknowledging reports of possible allergic reactions following vaccinations from one lot of the Company’s COVID-19 vaccine.  Moderna stated that it was fully cooperating with the California Department of Public Health in investigating the reported cases of allergic reactions.  On this news, Moderna’s stock price fell $4.64 per share, or 3.58%, to close at $125.01 per share on January 19, 2021.


If you are aware of any facts relating to this investigation, or purchased Moderna shares, you can assist this investigation by visiting contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.